ITEM 1.
|
FINANCIAL STATEMENTS
|
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
September 30, 2013
|
|
|
December 31, 2012
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
114,086
|
|
|
$
|
307,384
|
|
Restricted cash (Notes 6, 8, 9)
|
|
|
|
|
|
|
7,500
|
|
Accounts receivable
|
|
|
755
|
|
|
|
3,960
|
|
Contingent considerationcurrent (Notes 6, 9)
|
|
|
40,557
|
|
|
|
41,255
|
|
Income taxes receivable
|
|
|
404
|
|
|
|
554
|
|
Deferred income tax assetscurrent
|
|
|
316
|
|
|
|
644
|
|
Assets held for sale (Note 8)
|
|
|
|
|
|
|
300
|
|
Prepaid and other
|
|
|
1,705
|
|
|
|
1,442
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
157,823
|
|
|
|
363,039
|
|
|
|
|
Property, plant and equipment
|
|
|
2,180
|
|
|
|
2,655
|
|
Deferred income tax assetsnon-current
|
|
|
195
|
|
|
|
370
|
|
Contingent considerationnon-current (Notes 6, 9)
|
|
|
9,569
|
|
|
|
35,154
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
169,767
|
|
|
|
401,218
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
3,924
|
|
|
|
6,121
|
|
Accrued liabilities (Note 2)
|
|
|
1,407
|
|
|
|
2,515
|
|
Accrued restructuring charge (Note 5)
|
|
|
249
|
|
|
|
1,933
|
|
Deferred income
|
|
|
|
|
|
|
456
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
5,580
|
|
|
|
11,025
|
|
|
|
|
Uncertain tax position liabilities
|
|
|
1,874
|
|
|
|
1,875
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
7,454
|
|
|
|
12,900
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Share capital (Note 4)
|
|
|
|
|
|
|
|
|
Authorized
|
|
|
|
|
|
|
|
|
500,000,000 common shares without par value
|
|
|
|
|
|
|
|
|
5,000,000 first preference shares without par value, issuable in series
|
|
|
|
|
|
|
|
|
Issued and outstanding
|
|
|
466,229
|
|
|
|
471,712
|
|
Common shares
|
|
|
|
|
|
|
|
|
September 30, 2013 51,081,878 shares
|
|
|
|
|
|
|
|
|
December 31, 2012 51,589,405 shares
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
95,524
|
|
|
|
296,024
|
|
Accumulated deficit
|
|
|
(502,409
|
)
|
|
|
(482,387
|
)
|
Accumulated other comprehensive income
|
|
|
102,969
|
|
|
|
102,969
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
162,313
|
|
|
|
388,318
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity and liabilities
|
|
$
|
169,767
|
|
|
$
|
401,218
|
|
|
|
|
|
|
|
|
|
|
See the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.
3
QLT Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars except share and per share information)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
5,243
|
|
|
$
|
5,639
|
|
|
$
|
13,715
|
|
|
$
|
19,621
|
|
Selling, general and administrative
|
|
|
1,676
|
|
|
|
2,669
|
|
|
|
5,568
|
|
|
|
12,648
|
|
Depreciation
|
|
|
230
|
|
|
|
238
|
|
|
|
717
|
|
|
|
927
|
|
Restructuring charges (Note 5)
|
|
|
354
|
|
|
|
11,402
|
|
|
|
1,847
|
|
|
|
11,402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,503
|
|
|
|
19,948
|
|
|
|
21,847
|
|
|
|
44,598
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(7,503
|
)
|
|
|
(19,948
|
)
|
|
|
(21,847
|
)
|
|
|
(44,598
|
)
|
|
|
|
|
|
Investment and other income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net foreign exchange (losses) gains
|
|
|
(54
|
)
|
|
|
65
|
|
|
|
(36
|
)
|
|
|
(84
|
)
|
Interest income
|
|
|
39
|
|
|
|
59
|
|
|
|
175
|
|
|
|
147
|
|
Fair value change in contingent consideration (Notes 6, 9)
|
|
|
71
|
|
|
|
2,840
|
|
|
|
1,904
|
|
|
|
6,432
|
|
Other gains
|
|
|
64
|
|
|
|
21
|
|
|
|
100
|
|
|
|
102
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
120
|
|
|
|
2,985
|
|
|
|
2,143
|
|
|
|
6,597
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations before income taxes
|
|
|
(7,383
|
)
|
|
|
(16,963
|
)
|
|
|
(19,704
|
)
|
|
|
(38,001
|
)
|
|
|
|
|
|
(Provision for) Recovery of income taxes (Note 7)
|
|
|
(109
|
)
|
|
|
4,345
|
|
|
|
(434
|
)
|
|
|
3,798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(7,492
|
)
|
|
|
(12,618
|
)
|
|
|
(20,138
|
)
|
|
|
(34,203
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations, net of income taxes (Note 8)
|
|
|
96
|
|
|
|
94,078
|
|
|
|
116
|
|
|
|
89,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income and comprehensive (loss) income
|
|
|
(7,396
|
)
|
|
$
|
81,460
|
|
|
|
(20,022
|
)
|
|
$
|
54,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net (loss) income per common share (Note 10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
(0.15
|
)
|
|
$
|
(0.25
|
)
|
|
$
|
(0.40
|
)
|
|
$
|
(0.69
|
)
|
Discontinued operations
|
|
$
|
0.00
|
|
|
$
|
1.86
|
|
|
$
|
0.00
|
|
|
$
|
1.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per common share
|
|
$
|
(0.14
|
)
|
|
$
|
1.61
|
|
|
$
|
(0.39
|
)
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding (thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
51,082
|
|
|
|
50,600
|
|
|
|
50,851
|
|
|
|
49,592
|
|
See the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.
4
QLT Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Cash used in operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income and comprehensive (loss) income
|
|
$
|
(7,396
|
)
|
|
$
|
81,460
|
|
|
$
|
(20,022
|
)
|
|
$
|
54,879
|
|
Adjustments to reconcile net (loss) income to net cash used in operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
230
|
|
|
|
238
|
|
|
|
717
|
|
|
|
1,017
|
|
Stock-based compensation and restricted stock based compensation
|
|
|
137
|
|
|
|
140
|
|
|
|
279
|
|
|
|
5,692
|
|
Unrealized foreign exchange (gains) losses
|
|
|
69
|
|
|
|
(151
|
)
|
|
|
204
|
|
|
|
94
|
|
Deferred income taxes
|
|
|
108
|
|
|
|
949
|
|
|
|
566
|
|
|
|
1,600
|
|
Write-down of property, plant and equipment
|
|
|
|
|
|
|
1,056
|
|
|
|
|
|
|
|
1,056
|
|
Recovery on assets held for sale
|
|
|
(37
|
)
|
|
|
|
|
|
|
(212
|
)
|
|
|
|
|
Gain on sale of discontinued operations (Note 8)
|
|
|
|
|
|
|
(101,381
|
)
|
|
|
(743
|
)
|
|
|
(101,381
|
)
|
Gain on sale of property, plant and equipment
|
|
|
(4
|
)
|
|
|
|
|
|
|
(4
|
)
|
|
|
|
|
Fair value change in contingent consideration (Notes 6, 9)
|
|
|
761
|
|
|
|
|
|
|
|
1,249
|
|
|
|
|
|
Changes in non-cash operating assets and liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(47
|
)
|
|
|
(787
|
)
|
|
|
2,158
|
|
|
|
500
|
|
Inventories
|
|
|
|
|
|
|
1,318
|
|
|
|
|
|
|
|
361
|
|
Prepaid and other
|
|
|
690
|
|
|
|
1,482
|
|
|
|
(264
|
)
|
|
|
414
|
|
Accounts payable
|
|
|
486
|
|
|
|
2,195
|
|
|
|
(2,003
|
)
|
|
|
2,701
|
|
Income taxes receivable / payable
|
|
|
204
|
|
|
|
|
|
|
|
146
|
|
|
|
(297
|
)
|
Accrued liabilities
|
|
|
203
|
|
|
|
150
|
|
|
|
(1,158
|
)
|
|
|
(2,895
|
)
|
Accrued restructuring
|
|
|
(436
|
)
|
|
|
2,838
|
|
|
|
(1,633
|
)
|
|
|
2,838
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5,032
|
)
|
|
|
(10,493
|
)
|
|
|
(20,720
|
)
|
|
|
(33,421
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash provided by investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds from sale of property, plant and equipment and assets held for sale
|
|
|
30
|
|
|
|
25
|
|
|
|
239
|
|
|
|
25
|
|
Net proceeds from sale of discontinued operations (Note 8)
|
|
|
7,502
|
|
|
|
101,430
|
|
|
|
8,252
|
|
|
|
101,430
|
|
Purchase of property, plant and equipment
|
|
|
(129
|
)
|
|
|
(205
|
)
|
|
|
(129
|
)
|
|
|
(900
|
)
|
Net proceeds from sale of other assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250
|
|
Proceeds from mortgage receivable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,874
|
|
Proceeds from contingent consideration (Notes 6, 9)
|
|
|
8,483
|
|
|
|
6,457
|
|
|
|
25,035
|
|
|
|
19,841
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,886
|
|
|
|
107,707
|
|
|
|
33,397
|
|
|
|
126,520
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash (used in) provided by financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares repurchased, including fees
|
|
|
|
|
|
|
|
|
|
|
(14,079
|
)
|
|
|
|
|
Cash distribution paid to common shareholders (Note 4(a))
|
|
|
|
|
|
|
|
|
|
|
(200,000
|
)
|
|
|
|
|
Issuance of common shares
|
|
|
|
|
|
|
7,416
|
|
|
|
8,317
|
|
|
|
9,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,416
|
|
|
|
(205,762
|
)
|
|
|
9,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
52
|
|
|
|
258
|
|
|
|
(213
|
)
|
|
|
121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
10,906
|
|
|
|
104,888
|
|
|
|
(193,298
|
)
|
|
|
102,624
|
|
Cash and cash equivalents, beginning of period
|
|
|
103,180
|
|
|
|
203,333
|
|
|
|
307,384
|
|
|
|
205,597
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period
|
|
$
|
114,086
|
|
|
$
|
308,221
|
|
|
$
|
114,086
|
|
|
$
|
308,221
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary cash flow information
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Income taxes paid
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
|
|
391
|
|
See the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.
5
QLT Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
|
|
|
Additional
Paid-in
Capital
|
|
|
Accumulated
Deficit
|
|
|
Accumulated
Other
Comprehensive
Income
(1)
|
|
|
Total
Shareholders
Equity
|
|
|
Shares
|
|
|
Amount
|
|
|
|
|
|
(All amounts except share and per share information
are expressed in thousands of U.S. dollars)
|
|
Balance at January 1, 2012
|
|
|
48,927,742
|
|
|
$
|
458,118
|
|
|
$
|
296,003
|
|
|
$
|
(528,085
|
)
|
|
$
|
102,969
|
|
|
$
|
329,005
|
|
Exercise of stock options, for cash, at prices ranging from CAD $2.44 to CAD $7.23 per share
|
|
|
4,408,867
|
|
|
|
29,666
|
|
|
|
(8,257
|
)
|
|
|
|
|
|
|
|
|
|
|
21,409
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
5,902
|
|
|
|
|
|
|
|
|
|
|
|
5,902
|
|
Common share repurchase
|
|
|
(1,747,204
|
)
|
|
|
(16,072
|
)
|
|
|
2,376
|
|
|
|
|
|
|
|
|
|
|
|
(13,696
|
)
|
Net income and comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45,698
|
|
|
|
|
|
|
|
45,698
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2012
|
|
|
51,589,405
|
|
|
|
471,712
|
|
|
|
296,024
|
|
|
|
(482,387
|
)
|
|
|
102,969
|
|
|
|
388,318
|
|
Exercise of stock options, for cash, at prices ranging from CAD $2.44 to CAD $7.23 per share
|
|
|
631,685
|
|
|
|
5,072
|
|
|
|
(1,411
|
)
|
|
|
|
|
|
|
|
|
|
|
3,661
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
48
|
|
|
|
|
|
|
|
|
|
|
|
48
|
|
Common share repurchase
|
|
|
(1,691,479
|
)
|
|
|
(15,461
|
)
|
|
|
1,982
|
|
|
|
|
|
|
|
|
|
|
|
(13,479
|
)
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,427
|
)
|
|
|
|
|
|
|
(6,427
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2013
|
|
|
50,529,611
|
|
|
|
461,323
|
|
|
|
296,643
|
|
|
|
(488,814
|
)
|
|
|
102,969
|
|
|
|
372,121
|
|
Exercise of stock options, for cash, at prices ranging from CAD $2.44 to CAD $7.23 per share
|
|
|
552,267
|
|
|
|
4,906
|
|
|
|
(1,350
|
)
|
|
|
|
|
|
|
|
|
|
|
3,556
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
94
|
|
|
|
|
|
|
|
|
|
|
|
94
|
|
Cash distribution to common shareholders at $3.92 per share (Note 4(a))
|
|
|
|
|
|
|
|
|
|
|
(200,000
|
)
|
|
|
|
|
|
|
|
|
|
|
(200,000
|
)
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,199
|
)
|
|
|
|
|
|
|
(6,199
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2013
|
|
|
51,081,878
|
|
|
$
|
466,229
|
|
|
$
|
95,387
|
|
|
$
|
(495,013
|
)
|
|
$
|
102,969
|
|
|
$
|
169,572
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
122
|
|
Restricted stock compensation
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
|
|
|
|
|
|
15
|
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,396
|
)
|
|
|
|
|
|
|
(7,396
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2013
|
|
|
51,081,878
|
|
|
$
|
466,229
|
|
|
$
|
95,524
|
|
|
$
|
(502,409
|
)
|
|
$
|
102,969
|
|
|
$
|
162,313
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
At September 30, 2013 our accumulated other comprehensive income is entirely related to historical cumulative translation adjustments
resulting from the application of U.S. dollar reporting when the functional currency of QLT Inc. was the Canadian dollar.
|
See the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements.
6
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Throughout this Quarterly Report on Form 10-Q (this Report), the words we, us, our, the
Company and QLT refer to QLT Inc. and its wholly owned subsidiaries, QLT Plug Delivery, Inc., QLT Therapeutics, Inc. and QLT Ophthalmics, Inc., unless stated otherwise.
Business
QLT is a biotechnology
company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. On July 9, 2012, as a result of a comprehensive business and portfolio review by
our Board of Directors (the Board), we announced a new corporate strategy and plans to restructure our operations in order to concentrate our resources on our clinical development programs related to our synthetic retinoid, QLT091001,
for the treatment of certain inherited retinal diseases. In connection with this strategic restructuring of the Company, we engaged a financial advisor to determine whether to divest our business related to our commercial product, Visudyne
®
, and to explore the sale of our punctal plug drug delivery system technology (the PPDS Technology). On September 24, 2012, we completed the sale of our Visudyne business to
Valeant Pharmaceuticals International, Inc. (Valeant) pursuant to the terms of an asset purchase agreement (the Valeant Agreement). On April 3, 2013, we completed the sale of our PPDS Technology to Mati Therapeutics Inc.
(Mati) pursuant to the terms of an asset purchase agreement (the Mati Agreement). See Note 8
Discontinued Operations and Assets Held for Sale
.
1. CONDENSED SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in
the United States (US GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the SEC) for the presentation of interim financial information. Accordingly, certain information
and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed, or omitted, pursuant to such rules and regulations. These financial statements do not include all disclosures required
for the annual financial statements and should be read in conjunction with our audited consolidated financial statements and notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2012. All amounts
herein are expressed in United States dollars unless otherwise noted.
In managements opinion, the condensed consolidated financial
statements reflect all adjustments (including reclassifications and normal recurring adjustments) necessary to present fairly the financial position at September 30, 2013, and results of operations and cash flows for all periods presented. The
interim results presented are not necessarily indicative of results that can be expected for a full year.
The results of operations
relating to our PPDS Technology and Visudyne business have been excluded from continuing operations and reported as discontinued operations for the current and prior periods. See Note 8
Discontinued Operations and Assets Held for Sale
.
Principles of Consolidation
These
condensed consolidated financial statements include the accounts of QLT and its subsidiaries, all of which are wholly owned. All intercompany transactions have been eliminated.
Use of Estimates
The preparation of
financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as at the date of the
financial statements, and the reported amounts of expenses during the reporting
7
periods presented. Significant estimates include, but are not limited to, contingent consideration measured at fair value, allocation of overhead expenses to research and development, stock-based
compensation, restructuring costs, and provisions for taxes, tax assets and liabilities. Actual results may differ from estimates made by management.
Segment Information
We operate in one
industry segment, which is the business of developing, manufacturing, and commercializing opportunities in ophthalmology. As at the date of this report, our clinical development programs are solely focused on our synthetic retinoid, QLT091001. Our
chief operating decision maker reviews our operating results and manages our operations as a single operating segment. Our segment information excludes the results of businesses classified as discontinued operations.
Discontinued Operations and Assets Held for Sale
We consider assets to be held for sale when management approves and commits to a formal plan to actively market the assets for sale. Upon
designation as held for sale, the carrying value of the assets is recorded at the lower of their carrying value and their estimated fair values. We cease to record depreciation or amortization expense at that time.
The results of operations, including the gain on disposal for businesses that are classified as held for sale, are excluded from continuing
operations and reported as discontinued operations for all periods presented. Other than the provision of certain transition services described in Note 8
Discontinued Operations and Assets Held for Sale
, we have not had and do not expect
to have any significant continued involvement with the Visudyne business or the PPDS Technology following their sale. Amounts billed to Valeant and Mati in connection with the provision of these transition services are included within discontinued
operations.
Stock-Based Compensation
ASC topic 718 requires stock-based compensation expense, which is measured at fair value on the grant date, to be recognized in the statement
of operations over the period in which a grantee is required to provide services in exchange for the stock award. Compensation expense recognition provisions are applicable to new awards as well as previously granted awards which are modified,
repurchased or cancelled after the adoption date. We recognize stock based compensation expense based on the estimated grant date fair value using the Black-Scholes valuation model, adjusted for estimated forfeitures. When estimating forfeitures, we
consider voluntary terminations and trends of actual option forfeitures.
The Company has a Directors Deferred Share Unit Plan
(DDSU Plan) for our directors. We recognize compensation expense for Deferred Share Units (DSUs) based on the market price of the Companys stock. A vested DSU is convertible to cash only. The financial obligations
related to the future settlement of these DSUs are recognized as compensation expense and accrued liabilities as the DSUs vest. Each reporting period, these obligations are revalued for changes in the market value of QLTs common
shares.
During the three months ended September 30, 2013, the Company issued Restricted Stock Units (RSUs) to its
directors as consideration for their provision of future services as directors (see Note 4(d)). Restricted stock based compensation expense is measured based on the fair value market price of QLTs common shares on the grant date and is
recognized over the requisite service period, which coincides with the vesting period. RSUs can only be exchanged and settled for QLTs common shares, on a one-to-one basis, upon vesting.
Income Taxes
Income taxes are reported
using the asset and liability method, whereby deferred tax assets and liabilities are recognized for the future tax consequences attributable to: (i) differences between the financial statement carrying amounts of existing assets and
liabilities and their respective tax bases, and (ii) operating loss and tax
8
credit carry forwards using applicable enacted tax rates. An increase or decrease in these tax rates will increase or decrease the carrying value of future net tax assets resulting in an increase
or decrease to net income. Income tax credits, such as investment tax credits, are included as part of the provision for income taxes. The realization of our deferred tax assets is primarily dependent on the generation of sufficient capital gains
and taxable income prior to expiration of any loss carry forward balance. A valuation allowance is provided when it is more likely than not that a deferred tax asset may not be realized. Changes in valuation allowances are included in our tax
provision, or included within discontinued operations in the period of change.
Contingent Consideration
Contingent consideration arising from the sale of QLT USA and our Visudyne business is measured at fair value. The contingent consideration is
revalued at each reporting period and changes are included in continuing operations. See Note 6
Contingent Consideration.
Net (Loss)
Income Per Common Share
Basic net (loss) income per common share is computed using the weighted average number of common shares
outstanding during the period. Diluted net (loss) income per common share is computed in accordance with the treasury stock method, which uses the weighted average number of common shares outstanding during the period and also includes the dilutive
effect of common shares potentially issuable from outstanding stock options.
Fair Value of Financial Assets and Liabilities
The carrying values of cash and cash equivalents, trade receivables and payables, and contingent consideration approximate fair value. For cash
and cash equivalents, trade receivables and trade payables, we estimate fair value using the market approach. For contingent consideration, we estimate fair value using the income approach. The fair values of our financial instruments reflect the
amounts that would be received in connection with the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
Recently Issued Accounting Standards
In
July 2013, the FASB issued ASU No. 2013-11
Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists
. ASU No. 2013-11
requires companies to present an unrecognized tax benefit; or a portion of an unrecognized tax benefit; as a reduction to a deferred tax asset for a net operating loss, a similar tax loss, or a tax credit carryforward, unless certain conditions
exist. This update is effective prospectively for interim and annual periods beginning after December 31, 2013, with early adoption permitted. Retrospective application is also permitted. Management is currently assessing the impact of ASU
No. 2013-11 on the Companys consolidated financial statements.
2. ACCRUED LIABILITIES
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
September 30,
2013
|
|
|
December 31,
2012
|
|
Compensation
(1)
|
|
$
|
1,062
|
|
|
$
|
2,270
|
|
Directors Deferred Share Units compensation (DDSU)
|
|
|
180
|
|
|
|
96
|
|
Other
|
|
|
165
|
|
|
$
|
149
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,407
|
|
|
$
|
2,515
|
|
|
|
|
|
|
|
|
|
|
(1)
|
The decrease in the accrued compensation liability is primarily due to the pay-out of employee bonuses during the nine months ended
September 30, 2013.
|
9
3. FOREIGN EXCHANGE FACILITY
We have a foreign exchange facility (the Facility) with HSBC Bank of Canada for the sole purpose of entering
into foreign exchange contracts. The Facility previously allowed us to enter into a maximum of $50.0 million in spot or forward foreign exchange contracts for terms up to fifteen months. Effective April 23, 2013, we entered into an amendment
with HSBC Bank of Canada (the Amendment) which reduced the limit applicable to forward foreign exchange contracts to $12.5 million for terms up to one month. The Amendment also reduced the limit applicable to spot foreign exchange
contracts to $10.0 million. All other terms and conditions governing the Facility remain the same.
The Facility requires security in the
form of cash or money market instruments based on the contingent credit exposure for any outstanding foreign exchange transactions. At September 30, 2013 and December 31, 2012, no collateral has been pledged as security for this facility
given that we do not have any foreign exchange transactions outstanding.
4. SHARE CAPITAL
(a) Cash Distribution
On
June 27, 2013, we completed a $200.0 million special cash distribution, by way of a reduction of the paid-up capital of the Companys common shares (the Cash Distribution). The Cash Distribution was approved by the
Companys shareholders at QLTs annual and special shareholders meeting on June 14, 2013. All shareholders of record as at June 24, 2013 (the Record Date) were eligible to participate in the Cash Distribution
and received a payment of approximately $3.92 per share based upon the 51,081,878 common shares issued and outstanding on the Record Date.
(b) Share
Repurchase Program
On October 2, 2012, we commenced a normal course issuer bid to repurchase up to 3,438,683 of our common shares,
which represented 10% of our public float as of September 26, 2012. The bid was completed in March 2013. All purchases were effected in the open market through the facilities of the NASDAQ Stock Market, and in accordance with applicable
regulatory requirements. All common shares repurchased were cancelled. Total purchases under this program were 3,438,683 common shares at an average price of $7.86 per share, for a total cost of $27.0 million.
(c) Stock Options
On April 25, 2013, the
Companys board of directors amended and restated the QLT 2000 Incentive Stock Plan (the Plan) to increase the number of shares of the Companys common stock, without par value, available for grant under the Plan from 7,800,000
to 11,800,000 and to make certain other amendments to the Plan. The amendment and restatement of the Plan was subject to shareholder approval, which was obtained on June 14, 2013. On July 29, 2013, the Company filed a registration
statement to register the issuance of up to 4,000,000 additional common shares that may be issued under the Plan as a result of the amendment to the Plan.
On July 15, 2013, the Board of Directors granted an aggregate of 862,000 stock options to employees and 100,000 stock options to
directors. The stock options vest and become exercisable in thirty-six (36) successive and equal monthly installments beginning on the one-month anniversary of the date of grant and have an exercise price of CAD $4.54 per share, which is equal
to the closing price of the Companys common shares on the Toronto Stock Exchange on the date of grant.
We used the Black-Scholes
option pricing model to estimate the value of the options at each grant date. The Black-Scholes option pricing model was developed for use in estimating the value of traded options that have no vesting restrictions and are fully transferable. In
addition, option pricing models require the input of highly subjective assumptions, including the expected stock price volatility. We project expected volatility and expected life of our stock options based upon historical and other economic data
trended into future years. The risk-free
10
interest rate assumption is based upon observed interest rates appropriate for the expected life of our stock options. We used the following weighted average assumptions (no dividends are
assumed) to value the 962,000 stock options on the July 15, 2013 grant date:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Annualized volatility
|
|
|
46.1
|
%
|
|
|
|
|
|
|
46.1
|
%
|
|
|
46.8
|
%
|
Risk-free interest rate
|
|
|
2.1
|
%
|
|
|
|
|
|
|
2.1
|
%
|
|
|
1.0
|
%
|
Expected life (years)
|
|
|
6.5
|
|
|
|
|
|
|
|
6.5
|
|
|
|
3.8
|
|
The weighted average grant date fair value of stock options granted during the three and nine months ended
September 30, 2013 was CAD $2.18 (three months ended September 30, 2012$nil; nine months ended September 30, 2012CAD $2.55).
The impact on our results of operations of recording stock-based compensation for the three and nine months ended September 30, 2013 and
2012 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Research and development
|
|
$
|
77
|
|
|
$
|
39
|
|
|
$
|
171
|
|
|
$
|
1,503
|
|
Selling, general and administrative
|
|
|
45
|
|
|
|
40
|
|
|
|
90
|
|
|
|
1,764
|
|
Discontinued operations
|
|
|
|
|
|
|
61
|
|
|
|
3
|
|
|
|
2,425
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense before income taxes
|
|
|
122
|
|
|
|
140
|
|
|
|
264
|
|
|
|
5,692
|
|
Related income tax benefits
|
|
|
|
|
|
|
(5
|
)
|
|
|
|
|
|
|
(537
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation, net of income taxes
|
|
$
|
122
|
|
|
$
|
135
|
|
|
$
|
264
|
|
|
$
|
5,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at September 30, 2013, 959,249 stock options were unvested (December 30, 2012143,965). As at
September 30, 2013, the total estimated unrecognized compensation cost related to unvested stock options and the expected and weighted average periods over which such costs are expected to be recognized is as follows:
|
|
|
|
|
|
|
September 30,
2013
|
|
Unrecognized estimated compensation costs (in thousands of U.S. dollars)
|
|
$
|
1,786
|
|
Expected period of recognition of compensation cost (in months)
|
|
|
36
|
|
Expected weighted average period of compensation cost to be recognized (in years)
|
|
|
2.72
|
|
We issue new common shares upon exercise of stock options. The intrinsic value of stock options exercised and
the related cash from exercise of stock options during the three and nine months ended September 30, 2013 and 2012 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Intrinsic value of stock options exercised
|
|
$
|
|
|
|
$
|
6,199
|
|
|
$
|
2,142
|
|
|
$
|
7,858
|
|
Cash from exercise of stock options
|
|
|
|
|
|
|
9,302
|
|
|
|
7,217
|
|
|
|
11,293
|
|
(d) Deferred Share Units
On July 15, 2013, 88,000 DSUs were issued to directors in accordance with the terms of the DDSU Plan. The DSUs vest in
thirty-six (36) successive and equal monthly installments beginning on the first day of the first month after the date of grant. A vested DSU can only be settled by conversion to cash (no share is issued), and is automatically converted after
the director ceases to be a member of the Board unless the director is removed from the Board for just cause.
11
No cash payments were made under the DDSU Plan during the three and nine months ended
September 30, 2013. On June 4, 2012, a new board of directors was elected at the Companys annual shareholders meeting. As a result, upon departure of the previous board of directors, $2.5 million was paid out to these former
directors during the nine months ended September 30, 2012 in accordance with the terms of the DDSU Plan.
The impact on our results
of operations of recording DSU compensation for the three and nine months ended September 30, 2013 and 2012 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2012
(1)
|
|
|
2013
|
|
|
2012
(1)
|
|
Research and development
|
|
$
|
22
|
|
|
$
|
11
|
|
|
$
|
33
|
|
|
$
|
232
|
|
Selling, general and administrative
|
|
|
37
|
|
|
|
27
|
|
|
|
56
|
|
|
|
536
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred share unit compensation expense
|
|
|
59
|
|
|
|
38
|
|
|
|
89
|
|
|
|
768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
The DSU compensation for the nine months ended September 30, 2012 includes a $0.3 million
charge related to the accelerated vesting of 42,500 DSUs held by the previous board of directors as a result of the election of a new board of directors at the Companys annual shareholders meeting on June 4, 2012 and the
consequent departure of the previous board of directors.
|
(e) Restricted Stock Units
On July 15, 2013, 48,000 RSUs were issued to directors under the Plan in consideration of their provision of future services as
directors. The RSUs vest in three (3) successive and equal yearly installments on the date of each of the first three annual general meetings of the Company held after the date of grant. Upon vesting, each RSU represents the right to
receive one common share of the Company.
Restricted stock based compensation expense was measured at fair value based on the CAD $4.54
market price of QLTs common shares on the July 15, 2013 grant date. The weighted average grant date fair value of the RSUs during the three and nine months ended September 30, 2013 was therefore CAD $4.54. The full cost of the
restricted stock based compensation expense will be recognized over the three year vesting period, which is the requisite service period. During the three and nine months ended September 30, 2013, we recognized $0.02 million of restricted
stock based compensation expense as follows:
|
|
|
|
|
|
|
|
|
|
|
Three months
ended
September 30,
|
|
|
Nine months
ended
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2013
|
|
Research and development
|
|
$
|
6
|
|
|
$
|
6
|
|
Selling, general and administrative
|
|
|
9
|
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
Restricted stock unit compensation expense
|
|
$
|
15
|
|
|
$
|
15
|
|
|
|
|
|
|
|
|
|
|
As at September 30, 2013, 48,000 RSUs remain unvested. As at September 30, 2013, the total
estimated unrecognized compensation cost related to RSUs was $0.2 million and the weighted average periods over which such costs are expected to be recognized is 2.79 years.
5. RESTRUCTURING CHARGE
In July 2012 we restructured our operations in order to concentrate our resources on our clinical development programs
related to our synthetic retinoid, QLT091001, for the treatment of certain inherited retinal diseases. Following the sale of Visudyne to Valeant, we further reduced our workforce to better align the Companys resources with our corporate
objectives. Approximately 180 employees have been affected by the restructuring to date. Severance and support provisions have been made to assist these employees with outplacement. During the
12
year ended December 31, 2012, we recorded $16.9 million of restructuring charges of which $3.1 million was included in discontinued operations. During the three and nine months ended
September 30, 2013, we recorded further restructuring charges of $0.4 million and $1.8 million, respectively. Subsequent to September 30, 2013, we expect to record minimal additional restructuring charges related to severance, termination
benefits and outplacement support, as we complete final activities associated with this restructuring.
The details of our restructuring
accrual and activity are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U. S. dollars)
|
|
Employee
Termination
Costs
(1)
|
|
|
Asset
Write-downs
|
|
|
Contract
Termination
Costs
(2)
|
|
|
Other
|
|
|
Total
|
|
Restructuring charge
|
|
$
|
13,016
|
|
|
|
|
|
|
$
|
834
|
|
|
|
|
|
|
$
|
13,850
|
|
Foreign exchange
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20
|
|
Cash payments
|
|
|
(13,243
|
)
|
|
|
|
|
|
|
(718
|
)
|
|
|
|
|
|
|
(13,961
|
)
|
Discontinued operations
|
|
|
1,561
|
|
|
|
1,056
|
|
|
|
463
|
|
|
|
|
|
|
|
3,080
|
|
Non-cash portion
|
|
|
|
|
|
|
(1,056
|
)
|
|
|
|
|
|
|
|
|
|
|
(1,056
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2012
|
|
|
1,354
|
|
|
|
|
|
|
|
579
|
|
|
|
|
|
|
|
1,933
|
|
Restructuring charge
|
|
|
571
|
|
|
|
|
|
|
|
251
|
|
|
|
|
|
|
|
822
|
|
Foreign exchange
|
|
|
(47
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(47
|
)
|
Cash payments
|
|
|
(663
|
)
|
|
|
|
|
|
|
(356
|
)
|
|
|
|
|
|
|
(1,019
|
)
|
Discontinued operations
|
|
|
121
|
|
|
|
(153
|
)
|
|
|
47
|
|
|
|
|
|
|
|
15
|
|
Non-cash portion
|
|
|
|
|
|
|
153
|
|
|
|
|
|
|
|
|
|
|
|
153
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2013
|
|
|
1,336
|
|
|
|
|
|
|
|
521
|
|
|
|
|
|
|
|
1,857
|
|
Restructuring charge
|
|
|
668
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
671
|
|
Foreign exchange
|
|
|
(24
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(24
|
)
|
Cash payments
|
|
|
(1,605
|
)
|
|
|
|
|
|
|
(322
|
)
|
|
|
|
|
|
|
(1,927
|
)
|
Discontinued operations
|
|
|
11
|
|
|
|
(22
|
)
|
|
|
78
|
|
|
|
|
|
|
|
67
|
|
Non-cash portion
|
|
|
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2013
|
|
|
386
|
|
|
|
|
|
|
|
280
|
|
|
|
|
|
|
|
666
|
|
Restructuring charge
|
|
|
244
|
|
|
|
|
|
|
|
8
|
|
|
|
101
|
|
|
|
353
|
|
Foreign exchange
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20
|
|
Cash payments
|
|
|
(468
|
)
|
|
|
|
|
|
|
(211
|
)
|
|
|
(42
|
)
|
|
|
(721
|
)
|
Discontinued operations
|
|
|
(18
|
)
|
|
|
(37
|
)
|
|
|
(51
|
)
|
|
|
|
|
|
|
(106
|
)
|
Non-cash portion
|
|
|
|
|
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2013
|
|
$
|
164
|
|
|
$
|
|
|
|
$
|
26
|
|
|
$
|
59
|
|
|
$
|
249
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Costs include severance, termination benefits, and outplacement support.
|
(2)
|
Costs include lease costs related to excess office space.
|
6. CONTINGENT CONSIDERATION
Related to the Sale of QLT USA, Inc.
On October 1, 2009, we divested the Eligard
®
product line as part of the sale of
all of the shares of our U.S. subsidiary, QLT USA, Inc. (QLT USA) to TOLMAR Holding, Inc. (Tolmar) for up to an aggregate $230.0 million plus cash on hand of $118.3 million. Pursuant to the stock purchase agreement
with Tolmar, we received $20.0 million on closing and $10.0 million on October 1, 2010 and we are entitled to future consideration payable on a quarterly basis in amounts equal to 80% of the royalties paid under the license agreement
with Sanofi Synthelabo Inc. for the commercial marketing of Eligard in the U.S. and Canada, and the license agreement with MediGene Aktiengesellschaft which, effective March 1, 2011, was assigned to Astellas
13
Pharma Europe Ltd., for the commercial marketing of Eligard in Europe. The estimated fair value of these expected future quarterly payments is reflected as Contingent Consideration on our
Condensed Consolidated Balance Sheet and represents a non-cash investing activity. We are entitled to these payments until the earlier of our receipt of $200.0 million of such royalties or October 1, 2024.
During the three months ended September 30, 2013, proceeds received from the collection of the contingent consideration totaled
$9.3 million (three months ended September 30, 2012$9.3 million). Approximately $8.5 million of these proceeds have been reflected as cash provided by investing activities in the Condensed Consolidated Statements of Cash Flows
(three months ended September 30, 2012$6.5 million). The remaining $0.8 million of proceeds (three months ended September 30, 2012$2.8 million) was recognized as the fair value increase in contingent
consideration on the Condensed Consolidated Statement of Operations and Comprehensive Loss and is therefore reflected in the net loss and comprehensive loss line as part of the cash used in operating activities in the Condensed Consolidated
Statements of Cash Flows.
During the nine months ended September 30, 2013, proceeds received from the collection of the contingent
consideration totaled $28.2 million (nine months ended September 30, 2012$26.3 million). Approximately $25.0 million of these proceeds has been reflected as cash provided by investing activities in the Condensed
Consolidated Statements of Cash Flows (nine months ended September 30, 2012$19.8 million). The remaining $3.2 million (nine months ended September 30, 2012$6.5 million) of proceeds were recognized as the fair
value change in contingent consideration on the Condensed Consolidated Statement of Operations and Comprehensive Loss and is therefore reflected in the net loss line as part of the cash used in operating activities in the Condensed Consolidated
Statements of Cash Flows.
As of September 30, 2013, we have received an aggregate $151.4 million (December 31,
2012$123.3 million) of Eligard related contingent consideration and expect to receive the remaining $48.6 million (December 31, 2012$76.7 million) on a quarterly basis over approximately the next two years.
Related to the Sale of Visudyne
On
September 24, 2012, we completed the sale of our Visudyne business to Valeant. Pursuant to the Valeant Agreement, we received a payment of $112.5 million at closing, of which $7.5 million (previously held in escrow) was released to us
on September 26, 2013. These funds were held in escrow for one year following the closing date to satisfy any potential indemnification claims that Valeant may have had. Subject to the achievement of certain future milestones, we are also
eligible to receive the following additional consideration: (i) a milestone payment of $5.0 million if receipt of the registration required for commercial sale of the Qcellus lasers in the United States (the Laser Registration)
is obtained by December 31, 2013, $2.5 million if the Laser Registration is obtained after December 31, 2013 but before January 1, 2015, and $0 if the Laser Registration is obtained thereafter (the Laser Earn-Out
Payment); (ii) up to $5.0 million in each calendar year commencing January 1, 2013 (up to a maximum of $15.0 million in the aggregate) for annual net royalties exceeding $8.5 million pursuant to the Amended and
Restated PDT Product Development, Manufacturing and Distribution Agreement with Novartis Pharma AG (the Novartis Agreement) or from other third-party sales of Visudyne outside of the United States; and (iii) a royalty on net sales
attributable to new indications for Visudyne, if any should be approved by the United States Food and Drug Administration (the FDA).
On September 26, 2013, the FDA approved the premarket approval application (PMA) supplement for the Qcellus laser and on October 10,
2013, we invoiced Valeant for the $5.0 million Laser Earn-Out Payment. Valeant has disputed payment on the basis that it believes the Laser Earn-Out Payment remains contingent upon receipt of additional governmental authorizations with regard
to the Qcellus laser. While we believe that the Laser Earn-Out Payment is currently due and payable by Valeant, the outcome of any dispute is uncertain and we may have difficulty collecting the Laser Earn-Out Payment in full or in a timely manner.
As a result of the dispute, during the three and nine months ended September 30, 2013, we recorded a $0.8 million decrease in
the fair value of our contingent consideration pertaining to the Laser Earn-Out Payment to reflect the increased uncertainty related to collection risk. As at September 30, 2013, the $4.0 million
14
estimated fair value of the $20.0 million of aggregate potential contingent payments represents the fair value of the $5.0 million Laser Earn-Out Payment net of $1.0 million of
potential collection costs to account for the increased uncertainty related to collection risk. The remaining estimated fair value of the contingent consideration, which relates to estimated future net royalties pursuant to the Novartis Agreement
and is currently valued at nil, is based on historical sales, pricing, and foreign exchange data as well as expected competition and current exchange rates. The estimated $4.0 million is reflected as contingent consideration on our Condensed
Consolidated Balance Sheet and represents a non-cash investing activity.
We received no proceeds related to the collection of the
contingent consideration for the sale of Visudyne during the three and nine months ended September 30, 2013. In addition to the $0.8 million fair value decrease described above, during the nine months ended September 30, 2013 we also
recorded a net $0.5 million decrease in the fair value of our contingent consideration related to a revision in our estimate of potential future net royalties owing.
The above contingent consideration payments related to the sale of QLT USA and our Visudyne business are not generated from a migration or
continuation of activities and therefore are not direct cash flows of the divested business. See Note 8
Discontinued Operations and Assets Held for Sale
and Note 9
Financial Instruments and Concentration of Credit
Risk
.
7. INCOME TAXES
During the three and nine months ended September 30, 2013, the provision for income taxes was $0.1 million and
$0.4 million, respectively. The provision in each period primarily relates to the current period gain on the fair value change of our Eligard related contingent consideration. In addition, the provisions also reflect that we have insufficient
evidence to support current or future realization of the tax benefits associated with our development expenditures.
During the three and
nine months ended September 30, 2012, we recorded net income tax recoveries of $4.3 million and $3.8 million, respectively. The recovery in each period primarily related to the recognition of the tax benefit of our operating losses
from continuing operations. As a result of the sale of Visudyne to Valeant during the three months ended September 30, 2012, we benefited from a portion of our operating losses from continuing operations.
During the three and nine months ended September 30, 2013, the provision for income taxes related to discontinued operations was nil and
$0.2 million, respectively. The provision during the nine months ended September 30, 2013 primarily relates to the drawdown of a prepaid tax asset that was recorded in a prior year in connection with the intercompany transfer of certain
intellectual property and the subsequent sale of such technology to Mati in April 2013. The provisions for income taxes on discontinued operations also reflects that we have insufficient evidence to support current or future realization of the tax
benefits associated with expenditures related to our discontinued operations.
During the three and nine months ended September 30,
2012, the provision for income taxes related to discontinued operations was $5.3 million and $5.5 million, respectively. The provision in each period primarily related to the recognition of the tax cost of utilizing the tax shield
associated with our operating losses realized from continuing operations. The provision in each period also reflected that substantially all of the remaining balance of the tax impact of the gain on sale from discontinued operations was offset by
tax basis and other tax attributes (e.g. loss carryforwards) which previously had a valuation allowance.
As insufficient evidence exists
to support current or future realization of the tax benefits associated with the vast majority of our current and prior period operating expenditures, the benefit of certain tax assets was not recognized during the three and nine months ended
September 30, 2013 and 2012.
15
8. DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE
On September 24, 2012, we completed the sale of our Visudyne
®
business to Valeant pursuant to the Valeant Agreement. Under the terms of the Valeant Agreement, we received a payment of $112.5 million at closing and are also eligible to receive additional contingent consideration as follows: (i) up to
$5.0 million for the Laser Earn-Out Payment relating to the receipt of the Laser Registration (see Note 6
Contingent Consideration
and Note 11
Subsequent Events
in the Notes to the Unaudited Condensed Consolidated
Financial Statements for further information
)
; (ii) up to $15.0 million in contingent payments relating to royalties on sales of Visudyne under the Novartis Agreement or from other third party sales of Visudyne outside of the U.S.;
and (iii) a royalty on net sales of new indications for Visudyne, if any should be approved. In accordance with the terms of the Valeant Agreement, $7.5 million of the purchase price was held in escrow for one year following the closing
date to satisfy any potential indemnification claims that Valeant may have had. These funds were released from escrow to us on September 26, 2013. As such, the $7.5 million has been reclassified from Restricted Cash to Cash and Cash
Equivalents on our Consolidated Balance Sheet as at September 30, 2013. Following the divestiture, we did not have significant continuing involvement in the operations or cash flows of the Visudyne business other than the provision of certain
transition services to Valeant pursuant to our transition services agreement with Valeant. The activities related to transition services were complete as at August 31, 2013.
On April 3, 2013, we completed the sale of our PPDS Technology to Mati pursuant to the terms of the Mati Agreement. Prior to the
completion of the sale, Mati purchased an exclusive option to acquire the assets related to our PPDS Technology in exchange for $0.5 million. We recognized the $0.5 million over the stipulated 90 day option term in discontinued
operations due to a continuing performance obligation related to the maintenance of the related intellectual property. In accordance with the terms of the Mati Agreement, we received an additional payment of approximately $0.7 million upon
closing. Furthermore, we are eligible to receive future potential payments upon completion of certain product development and commercialization milestones that could reach $19.5 million (or exceed that amount if more than two products are
commercialized), a low single digit royalty on world-wide net sales of all products using or developed from the PPDS Technology and a fee on payments received by Mati in respect of the PPDS Technology other than net sales. Under the terms of the
Mati Agreement, we do not have any significant ongoing involvement in the operations or cash flows related to the PPDS Technology other than minor transition services which we have agreed to provide. The activities related to transition services
were complete as at September 30, 2013.
The results of operations relating to both our PPDS Technology and our Visudyne business
have been excluded from continuing operations and reported as discontinued operations for all periods presented. In addition, as at December 31, 2012, approximately $0.3 million of property, plant and equipment related to our former PPDS
Technology and Visudyne business were reclassified as held for sale for disclosure purposes in the Consolidated Balance Sheets. As at September 30, 2013, these assets have been sold.
Operating results of our PPDS Technology and our Visudyne business included in discontinued operations are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
September 30,
|
|
|
September 30,
|
|
(In thousands of U.S. dollars)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Total revenues
|
|
$
|
|
|
|
$
|
8,490
|
|
|
$
|
|
|
|
$
|
25,470
|
|
Recovery on (write-down of) assets held for sale
(1)
|
|
|
37
|
|
|
|
(1,211
|
)
|
|
|
212
|
|
|
|
(1,211
|
)
|
Operating pre-tax income (loss)
|
|
|
83
|
|
|
|
(2,004
|
)
|
|
|
(391
|
)
|
|
|
(6,805
|
)
|
Gain on sale of discontinued operations
|
|
|
|
|
|
|
101,381
|
(3)
|
|
|
743
|
(2)
|
|
|
101,381
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-tax income (loss)
(4)
|
|
|
83
|
|
|
|
99,377
|
|
|
|
352
|
|
|
|
94,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recovery of (provision for) income taxes
|
|
|
13
|
|
|
|
(5,299
|
)
|
|
|
(236
|
)
|
|
|
(5,494
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income from discontinued operations
|
|
$
|
96
|
|
|
$
|
94,078
|
|
|
$
|
116
|
|
|
$
|
89,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
(1)
|
Relates to an increase in fair value on previously impaired equipment in connection with the sale of our PPDS Technology to Mati.
|
(2)
|
During the nine months ended September 30, 2013, the net gain of $0.7 million represents total proceeds of $1.2 million related to
the sale of our PPDS Technology to Mati in April 2013, net of $0.3 million of related transaction costs and the $0.2 million carrying value of certain equipment sold, which was previously classified as held for sale.
|
(3)
|
During the three and nine months ended September 30, 2012, the net gain of $101.4 million relates to the gain on the sale of our Visudyne
business to Valeant in September 2012.
|
(4)
|
The results for the three and nine months ended September 30, 2013 includes operating pre-tax income of $0.1 million and operating
pre-tax losses of $0.3 million, respectively related to our PPDS Technology. However, the three and nine months ended September 30, 2012 includes $5.3 million and $18.2 million of pre-tax operating losses related to our PPDS
Technology, respectively. The remaining amounts relate to Visudyne.
|
9. FINANCIAL INSTRUMENTS AND CONCENTRATION OF CREDIT RISK
We have various financial instruments that must be measured under the fair value standard including cash and cash
equivalents, restricted cash, contingent consideration and, from time to time, forward currency contracts. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy.
The following tables provide information about our assets and liabilities that are measured at fair value on a recurring basis at
September 30, 2013 and December 31, 2012 and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying Value
September 30, 2013
|
|
|
Fair Value Measurements at September 30, 2013
|
|
(In thousands of U.S. dollars)
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
114,086
|
|
|
$
|
114,086
|
|
|
$
|
|
|
|
$
|
|
|
Contingent consideration
(1)
|
|
|
50,126
|
|
|
|
|
|
|
|
|
|
|
|
50,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
164,212
|
|
|
$
|
114,086
|
|
|
$
|
|
|
|
$
|
50,126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carrying Value
December 31, 2012
|
|
|
Fair Value Measurements at December 31, 2012
|
|
(In thousands of U.S. dollars)
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
307,384
|
|
|
$
|
307,384
|
|
|
$
|
|
|
|
$
|
|
|
Restricted cash
|
|
|
7,500
|
|
|
|
7,500
|
|
|
|
|
|
|
|
|
|
Contingent consideration
(1)
|
|
|
76,409
|
|
|
|
|
|
|
|
|
|
|
|
76,409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
391,293
|
|
|
$
|
314,884
|
|
|
$
|
|
|
|
$
|
76,409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
To estimate the fair value of contingent consideration we use a discounted cash flow model based on estimated timing and amount of future cash
flows. As at September 30, 2013, and December 31, 2012, we discounted the future cash flows using cost of capital rates of 9% and 8%, respectively, for the contingent consideration related to the Eligard and Visudyne royalties and 2.0% and
3.5%, respectively, for the contingent consideration related to the Laser Registration, determined by management after considering available market and industry information. Future cash flows were estimated by utilizing external market research to
estimate market size, to which we applied market share, pricing and foreign exchange assumptions based on historical sales data, expected competition and current exchange rates. If the discount rate were to increase by 1%, the contingent
consideration related to the sale of QLT USA would decrease by $0.2 million, from $46.2 million to $45.9 million, and the contingent consideration related to the sale of our Visudyne business would decrease by a negligible amount. If
estimated future sales of Eligard were to
|
17
|
decrease by 10%, the contingent consideration related to the sale of QLT USA would decrease by $0.2 million, from $46.2 million to $46.0 million. If estimated future sales of
Visudyne were to decrease by 10%, the contingent consideration related to the sale of our Visudyne business would decrease by a negligible amount.
|
The following table represents a reconciliation of our asset (contingent consideration) measured and recorded at fair value on a recurring
basis, using significant unobservable inputs (Level 3):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3
|
|
(In thousands of U.S. dollars)
|
|
Related to Sale
of QLT USA
|
|
|
Related to Sale
of Visudyne
|
|
|
Total
|
|
Balance at January 1, 2012
|
|
$
|
99,947
|
|
|
$
|
|
|
|
$
|
99,947
|
|
Transfers / Additions to Level 3
|
|
|
|
|
|
|
5,364
|
|
|
|
5,364
|
|
Settlements
|
|
|
(37,117
|
)
|
|
|
|
|
|
|
(37,117
|
)
|
Fair value change in contingent consideration
|
|
|
8,365
|
|
|
|
(150
|
)
|
|
|
8,215
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2012
|
|
|
71,195
|
|
|
|
5,214
|
|
|
|
76,409
|
|
Transfers / Additions to Level 3
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlements
|
|
|
(10,863
|
)
|
|
|
|
|
|
|
(10,863
|
)
|
Fair value change in contingent consideration
|
|
|
1,307
|
|
|
|
(512
|
)
|
|
|
795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 31, 2013
|
|
|
61,639
|
|
|
|
4,702
|
|
|
|
66,341
|
|
Transfers / Additions to Level 3
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlements
|
|
|
(8,009
|
)
|
|
|
|
|
|
|
(8,009
|
)
|
Fair value change in contingent consideration
|
|
|
1,014
|
|
|
|
24
|
|
|
|
1,038
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2013
|
|
$
|
54,644
|
|
|
$
|
4,726
|
|
|
$
|
59,370
|
|
Transfers / Additions to Level 3
|
|
|
|
|
|
|
|
|
|
|
|
|
Settlements
|
|
|
(9,315
|
)
|
|
|
|
|
|
|
(9,315
|
)
|
Fair value change in contingent consideration
|
|
|
832
|
|
|
|
(761
|
)
|
|
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2013
|
|
$
|
46,161
|
|
|
$
|
3,965
|
|
|
$
|
50,126
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Comprised of $40.6 million as current portion of contingent consideration and $9.6 million as long-term portion of contingent consideration on
the Consolidated Balance Sheet.
|
As at September 30, 2013 and December 31, 2012, we had no outstanding forward
foreign currency contracts.
Other financial instruments that potentially subject us to concentration of credit risk include our cash,
cash equivalents, accounts receivable and contingent consideration. To limit our credit exposure in regards to cash and cash equivalents, we deposit our cash with high quality financial institutions and the primary goals of our treasury policy are
capital preservation and liquidity. Our treasury policy limits investments to certain money market securities issued by governments, financial institutions and corporations with investment-grade credit ratings, and places restrictions on maturities
and concentration by issuer.
18
10. NET (LOSS) INCOME PER SHARE
The following table sets out the computation of basic and diluted net (loss) income per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
Nine months ended
|
|
|
September 30,
|
|
|
September 30,
|
|
(In thousands of U.S. dollars, except share and per share data)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Numerator:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(7,492
|
)
|
|
$
|
(12,618
|
)
|
|
$
|
(20,138
|
)
|
|
$
|
(34,203
|
)
|
(Loss) income from discontinued operations, net of income taxes
|
|
|
96
|
|
|
|
94,078
|
|
|
|
116
|
|
|
|
89,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income and comprehensive (loss) income
|
|
$
|
(7,396
|
)
|
|
$
|
81,460
|
|
|
$
|
(20,022
|
)
|
|
$
|
54,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: (thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding
|
|
|
51,082
|
|
|
|
50,600
|
|
|
|
50,851
|
|
|
|
49,592
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted average common shares outstanding
|
|
|
51,082
|
|
|
|
50,600
|
|
|
|
50,851
|
|
|
|
49,592
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net (loss) income per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
(0.15
|
)
|
|
$
|
(0.25
|
)
|
|
$
|
(0.40
|
)
|
|
$
|
(0.69
|
)
|
Discontinued operations
|
|
$
|
0.00
|
|
|
$
|
1.86
|
|
|
$
|
0.00
|
|
|
$
|
1.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per common share
|
|
$
|
(0.14
|
)
|
|
$
|
1.61
|
|
|
$
|
(0.39
|
)
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three and nine months ended September 30, 2013, 1,074,348 stock options (2012 3,513,012
stock options) were excluded from the calculation of diluted net income (loss) per common share because their effect was anti-dilutive.
11. SUBSEQUENT EVENTS
Pursuant to the terms of the Valeant Agreement, we are eligible to receive a Laser Earn-Out Payment contingent on the
receipt of the Laser Registration from the FDA. On September 26, 2013, the FDA approved the PMA supplement for the Qcellus laser and on October 10, 2013, we invoiced Valeant for the $5.0 million Laser Earn-Out Payment. Valeant has disputed
payment on the basis that it believes the Laser Earn-Out Payment remains contingent upon receipt of additional governmental authorizations with respect to the Qcellus laser. While we believe that the Laser Earn-Out Payment is currently due and
payable by Valeant, the outcome of any dispute is uncertain and we may have difficulty collecting the Laser Earn-Out Payment in full or in a timely manner. As such, during the three and nine months ended September 30, 2013, we recorded a $0.8
million decrease in the fair value of our contingent consideration pertaining to the Laser Earn-Out Payment to reflect the increased uncertainty related to collection risk. As at September 30, 2013, the Laser Earn-Out Payment has been recorded
at its estimated fair value of $4.0 million, which reflects the $5.0 million Laser Earn-Out Payment net of $1.0 million of potential collection costs.
19
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following information should be read in conjunction with the accompanying unaudited interim condensed
consolidated financial statements and notes thereto, which are prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and our audited consolidated financial statements and notes thereto
included as part of our Annual Report on Form 10-K for the year ended December 31, 2012 (our 2012 Annual Report).
All of
the following amounts are expressed in U.S. dollars unless otherwise indicated.
Note regarding Trademarks
The following words used in this Report are trademarks:
|
|
|
Eligard
®
is a registered trademark of Sanofi S.A.
|
|
|
|
Visudyne
®
is a registered trademark of Novartis AG.
|
|
|
|
Qcellus is a trademark of Valeant Pharmaceuticals International, Inc.
|
Any words used in this Report that are trademarks but are not referred to above are the property of their respective owners.
Overview
Corporate Restructuring
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical
needs of patients and clinicians worldwide. On July 9, 2012, as a result of a comprehensive business and portfolio review by our Board of Directors (the Board), we announced a new corporate strategy and plans to restructure our
operations in order to concentrate our resources on our clinical development programs related to our synthetic retinoid, QLT091001, for the treatment of certain inherited retinal diseases. In connection with the strategic restructuring of the
Company, over the course of 2012 and 2013 we completed a significant reduction in our workforce of approximately 180 employees. Currently, our remaining employees are focused on the development of QLT091001.
In connection with the restructuring, following the departure of Robert Butchofsky, the Companys former President and Chief Executive
Officer, on August 2, 2012, the Board formed an Executive Transition Committee currently composed of Directors Jeffrey Meckler and Dr. John Kozarich to perform the function of the Chief Executive Officer on an interim basis while the
Board determines the resources and management necessary to pursue the Companys new strategy. Jeffrey Meckler serves as Chairman of the Executive Transition Committee.
Sales of Assets and Discontinued Operations
Visudyne
®
In September 2012, in connection with the strategic restructuring, we sold our only commercial product, Visudyne, to Valeant Pharmaceuticals
International, Inc. (Valeant). Pursuant to the asset purchase agreement between the Company and Valeant (the Valeant Agreement), we sold all of our assets related to our Visudyne business, including the Qcellus laser then
under development by us, for $112.5 million in upfront consideration, contingent payments up to $20.0 million, and a royalty on net sales of new indications for Visudyne, if any should be approved. We are entitled to the contingent
payments upon the achievement of certain milestones, including: (i) $5.0 million if receipt of the registration required for commercial sale of the Qcellus lasers in the United States (the Laser Registration) is obtained by
December 31, 2013, $2.5 million if the Laser Registration
20
is obtained after December 31, 2013 but before January 1, 2015 and $0 if the Laser Registration is obtained thereafter (the Laser Earn-Out Payment) and (ii) up to
$5.0 million in each calendar year commencing January 1, 2013 (up to a maximum of $15.0 million in the aggregate) for annual net royalties exceeding $8.5 million received by Valeant under the license agreement with Novartis
Pharma AG (Novartis), which we transferred to Valeant in connection with the sale, or from other third-party sales of Visudyne outside of the United States.
On September 26, 2013, the FDA approved the premarket approval application (PMA) supplement for the Qcellus laser and we have invoiced
Valeant for the $5.0 million Laser Earn-Out Payment. Valeant has disputed payment on the basis that it believes the Laser Earn-Out Payment remains contingent upon receipt of additional governmental authorizations with respect to the Qcellus
laser. While we believe that the Laser Earn-Out Payment is currently due and payable by Valeant, the outcome of any dispute is uncertain and we may have difficulty collecting the Laser Earn-Out Payment in full or in a timely manner.
In connection with the sale of our Visudyne business, we entered into a transition services agreement with Valeant, pursuant to which we have
been providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. In the third quarter of 2013, we completed all of our transition services under our transition services agreement with Valeant,
including with respect to Visudyne and the commercial sale of Visudyne, and with respect to obtaining FDA approval of the Qcellus laser through the PMA process.
Punctal Plug Delivery Program
On
April 3, 2013, we completed the sale of our punctal plug drug delivery system technology (the PPDS Technology) to Mati Therapeutics Inc. (Mati), a development company founded by Robert Butchofsky, our former
President and Chief Executive Officer. After a lengthy process of seeking a buyer for the PPDS Technology, on December 24, 2012, we granted Mati a
90-day
exclusive option to acquire the PPDS
Technology in exchange for $0.5 million. On April 3, 2013, following Matis exercise of the option, we entered into an asset purchase agreement with Mati and completed the sale of the PPDS Technology to Mati. Under the terms of our
asset purchase agreement with Mati (the Mati Agreement), we received an additional payment of approximately $0.8 million at closing and are eligible to receive potential payments upon the satisfaction of certain product development
and commercialization milestones that could reach $19.5 million (or exceed that amount if more than two products are commercialized), a low single digit royalty on world-wide net sales of all products using or developed from the PPDS Technology
and a fee on payments received by Mati in respect of the PPDS Technology other than net sales.
Eligard
On October 1, 2009, we divested the Eligard line of products to TOLMAR Holding, Inc. (Tolmar) as part of the sale of all of
the shares of our U.S. subsidiary, QLT USA, Inc. (QLT USA). Pursuant to the stock purchase agreement, we are entitled to future consideration payable quarterly in amounts equal to 80% of the royalties paid under the license agreement
with Sanofi Synthelabo Inc. (Sanofi) for the commercial marketing of Eligard in the U.S. and Canada, and the license agreement with MediGene Aktiengesellschaft (MediGene), which, effective March 1, 2011, was assigned to
Astellas Pharma Europe Ltd. (Astellas), for the commercial marketing of Eligard in Europe. The estimated fair value of the expected future quarterly payments is reflected as Contingent Consideration on our Consolidated Balance Sheet. We
are entitled to these quarterly payments until the earlier of our receipt of $200.0 million or October 1, 2024. As of September 30, 2013, we had received an aggregate of
$
151.4 million of contingent consideration. While we
expect to receive the full amount of contingent consideration in approximately the next two years, our continued receipt of contingent consideration under the stock purchase agreement is dependent upon sales of Eligard by Sanofi and Astellas, which
could vary significantly due to competition, manufacturing difficulties and other factors.
21
Return of Capital
On June 27, 2013, we completed a special cash distribution to shareholders in the amount of $200.0 million, by way of a reduction of
the paid-up capital of the common shares, resulting in the return of approximately $3.92 per share (the Cash Distribution). The Cash Distribution was made to shareholders without Canadian withholding taxes of up to 25% being
payable, pursuant to an Advance Tax Ruling received from Canadian tax authorities. The Cash Distribution was approved by shareholders at our 2013 annual general and special meeting of shareholders on June 14, 2013 and was paid to shareholders
of record as of June 24, 2013.
On October 2, 2012, we commenced a normal course issuer bid to repurchase up to 3,438,683 of our
common shares, being 10% of our public float as of September 26, 2012, the maximum amount permitted under the Toronto Stock Exchange normal course issuer bid rules. The share repurchase program was implemented pursuant to an automatic share
purchase plan, in accordance with applicable Canadian and U.S. securities legislation. Total repurchases under the program, which we completed in March 2013, were 3,438,683 common shares at an average price of $7.86 per share, for a total cost of
$27.0 million. All purchases were effected in the open market through the facilities of the NASDAQ Stock Market, and in accordance with regulatory requirements. All common shares repurchased were cancelled.
Research and Development
Our
research and development efforts are focused on QLT091001, an oral synthetic retinoid replacement therapy for 11-
cis
-retinal, a key biochemical component of the visual retinoid cycle.
We are currently evaluating QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa
(RP). Results from our initial Phase Ib clinical proof-of-concept study in patients with LCA and RP were reported for the 14 subject cohort of LCA patients in 2011 and for the 18 subject cohort of early-onset RP patients in March
2012. Dosing in our retreatment study in these subjects is now completed and follow-up of subjects is ongoing. The retreatment study was initiated in order to examine the safety, efficacy and tolerability of repeat dosing cycles of QLT091001
administered over seven days. We expect to complete our preliminary analysis of the data in the first quarter of 2014. We are also continuing our dialogue with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) with respect to the design and protocol requirements for potential pivotal trials in LCA and RP patients.
22
QLT091001 has received orphan drug designations for the treatment of LCA (due to inherited
mutations in the
LRAT
and
RPE65
genes) and RP (all mutations) by the FDA, and for the treatment of LCA and RP (all mutations) by the EMA. The drug has also been granted two Fast Track designations by the FDA for the treatment of LCA
and RP due to inherited mutations in the
LRAT
and
RPE65
genes. In May 2011, the United States Patent and Trademark Office issued Patent No. 7,951,841, a key patent related to this program, covering various methods of use of
QLT091001 in the treatment of diseases associated with an endogenous 11-cis-retinal deficiency, expiring on July 27, 2027, including the period of Patent Term Adjustment.
RESULTS OF OPERATIONS
The following
table sets out our net loss from operations for the three and nine months ended September 30, 2013 and 2012:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
September 30,
|
|
|
Nine months ended
September 30,
|
|
(In thousands of U.S. dollars, except per share data)
|
|
2013
|
|
|
2012
|
|
|
2013
|
|
|
2012
|
|
Net (loss) income and comprehensive (loss) income
|
|
$
|
(7,396
|
)
|
|
$
|
81,460
|
|
|
$
|
(20,022
|
)
|
|
$
|
54,879
|
|
Basic and diluted net loss per common share
|
|
|
(0.14
|
)
|
|
|
1.61
|
|
|
|
(0.39
|
)
|
|
|
1.11
|
|
Detailed discussion and analysis of our results of operations are as follows:
Costs and Expenses
Research and Development
Research and development, or R&D, expenditures all relate to our synthetic retinoid program. For the three months ended
September 30, 2013, R&D expenditures were $5.2 million compared to $5.6 million for the same period in 2012. The $0.4 million (7%) decrease was primarily due the impact of our 2012 R&D workforce reduction.
For the nine months ended September 30, 2013, R&D expenditures were $13.7 million compared to $19.6 million for the same period
in 2012. The $5.9 million (30%) decrease was primarily due to: (i) $4.7 million of savings resulting from our 2012 workforce reduction and reduced spending on our synthetic retinoid program, as well as higher spending in 2012 related to
the completion of certain early stage safety studies and manufacturing activities required to support our clinical studies; and (ii) the $1.2 million impact of the accelerated vesting of certain stock options recorded in 2012 in connection with
the election of a new Board of Directors on June 4, 2012.
23
Selling, General and Administrative Expenses
For the three months ended September 30, 2013, selling, general and administration, or SG&A, expenditures were $1.7 million compared
to $2.7 million for the same period in 2012. The $1.0 million (37 %) decrease was primarily due to savings resulting from our 2012 workforce reduction, a decrease in discretionary spending and other restructuring initiatives.
For the nine months ended September 30, 2013 SG&A expenditures were $5.6 million compared to $12.6 million for the same period in
2012. The $7.1 million (56%) decrease was primarily due to: (i) $5.8 million of savings resulting from our 2012 workforce reduction, a decrease in discretionary spending and other restructuring initiatives; (ii) a $0.9 million charge
incurred in 2012 related to the accelerated vesting of employee stock options related to the election of a new Board of Directors on June 4, 2012; and (iii) higher compensation expense of $0.3 million incurred in 2012 related to
accelerated vesting of the previous directors deferred stock units.
Restructuring Charges
During the year ended December 31, 2012, we restructured our operations to focus our resources on our clinical development programs
related to our synthetic retinoid, QLT091001, for the treatment of certain inherited retinal diseases. Following the sale of Visudyne to Valeant, we further reduced our workforce to better align the Companys resources with our corporate
objectives. Approximately 180 employees have been affected by the restructuring plan to date. Severance and support provisions were made to assist these employees with outplacement.
During the three and nine months ended September 30, 2013, we recorded further restructuring charges of $0.4 million and $1.8
million, respectively. Annualized operating savings resulting from the restructuring are expected to be approximately $24.9 million related to the workforce reduction. See Note 5
Restructuring Charges
in the Notes to the Unaudited
Condensed Consolidated Financial Statements.
Investment and Other Income
Net Foreign Exchange Gains (Losses)
For the three and nine months ended September 30, 2013 and 2012, net foreign exchange gains (losses) comprised gains and losses from the
impact of foreign exchange fluctuations on our monetary assets and liabilities that are denominated in currencies other than the U.S. dollar (principally the Canadian dollar). See
Liquidity and Capital Resources Interest and Foreign
Exchange Rates
below.
Fair Value Change in Contingent Consideration
As part of the sale of all of the shares of QLT USA to Tolmar, we are entitled to receive up to $200.0 million in consideration payable on a
quarterly basis in amounts equal to 80% of the royalties paid under the license agreements with each of Sanofi and Astellas (formerly with MediGene) for the commercial marketing of Eligard in the U.S., Canada, and Europe. At September 30, 2013,
there was up to $48.6 million remaining to be paid to us by Tolmar. The $46.2 million fair value of this amount is reported as part of Contingent Consideration on our Consolidated Balance Sheet, and is estimated using a discounted cash flow model.
On September 24, 2012, we completed the sale of Visudyne to Valeant. Pursuant to the Valeant Agreement, we received a payment of
$112.5 million at closing, of which $7.5 million (previously held in escrow) was released to us on September 26, 2013. These funds were held in escrow for one year following the closing date to satisfy any potential indemnification claims that
Valeant may have had. Subject to the achievement of certain future milestones, we are also eligible to receive the following additional consideration: (i) a milestone payment of $5.0 million if the Laser Registration is obtained by
December 31, 2013, $2.5 million if the Laser Registration is obtained after December 31, 2013 but before January 1, 2015, and $0 if the Laser Registration is obtained thereafter (Laser Earn-Out Payment); (ii) up to
$5.0 million in each calendar year commencing January 1, 2013 (up to a maximum of $15.0 million in the aggregate) for annual net royalties exceeding $8.5 million pursuant to
24
the Amended and Restated PDT Product Development, Manufacturing and Distribution Agreement with Novartis Pharma AG or from other third-party sales of Visudyne outside of the United States; and
(iii) a royalty on net sales attributable to new indications for Visudyne, if any should be approved by the FDA.
On
September 26, 2013, the FDA approved the premarket approval application (PMA) supplement for the Qcellus laser and on October 10, 2013, we invoiced Valeant for the $5.0 million Laser Earn-Out Payment. Valeant has disputed payment on the
basis that it believes the Laser Earn-Out Payment remains contingent upon receipt of additional governmental authorizations for the Qcellus laser. While we believe that the Laser Earn-Out Payment is currently due and payable by Valeant, the outcome
of any dispute is uncertain and we may have difficulty collecting the Laser Earn-Out Payment in full or in a timely manner.
As a result
of the dispute, during the three and nine months ended September 30, 2013, we recorded a $0.8 million decrease in the fair value of our contingent consideration pertaining to the Laser Earn-Out Payment to reflect the increased uncertainty
related to collection risk. In addition to the $0.8 million fair value decrease described above, during the nine months ended September 30, 2013 we also recorded a net $0.5 million decrease in the fair value of our contingent consideration
related to a revision in our estimate of potential future net royalties owing. As at September 30, 2013, the $4.0 million estimated fair value of the $20.0 million of aggregate potential contingent payments represents the fair value of the $5.0
million Laser Earn-Out Payment net of $1.0 million of potential collection costs to account for the increased uncertainty related to collection risk. The remaining estimated fair value of the contingent consideration, which relates to estimated
future net royalties pursuant to the Novartis Agreement is currently valued at nil based on historical sales, pricing, and foreign exchange data as well as expected competition and current exchange rates. The estimated $4.0 million is reflected as
contingent consideration on our Condensed Consolidated Balance Sheet and represents a non-cash investing activity.
Contingent
consideration is revalued at each reporting period and is positively impacted by the passage of time, since all remaining expected cash flows move closer to collection, thereby increasing their present value. The fair value change in contingent
consideration is also impacted by the projected amount and timing of expected future cash flows and the cost of capital applied to discount these cash flows.
For the three months ended September 30, 2013, we recorded a net fair value gain of $0.1 million compared to a net fair value gain of
$2.8 million for the same period in 2012. For the nine months ended September 30, 2013, we recorded a net fair value gain of $1.9 million compared to a net fair value gain of $6.4 million for the same period in 2012. The fair value decreases
are primarily due to the impact of the time value of money and cash collected during the period, which decreases the balance of future expected cash flows owed to us.
Income from Discontinued Operations
As a result of our comprehensive business and portfolio review in July 2012, we announced a new corporate strategy and plans to restructure our
operations to focus our resources on our clinical development programs related to our synthetic retinoid, QLT091001, for the treatment of certain inherited retinal diseases. On September 24, 2012, we completed the sale of our Visudyne business
to Valeant pursuant to the Valeant Agreement (see
Sale of Assets and Discontinued OperationsVisudyne
above for additional information). On April 3, 2013, we completed the sale of our PPDS Technology to Mati pursuant to the terms of
the Mati Agreement. Prior to the completion of the sale, Mati purchased an exclusive option to acquire the assets related to our PPDS Technology in exchange for $0.5 million. We recognized the $0.5 million over the stipulated 90 day option term in
discontinued operations due to a continuing performance obligation related to the maintenance of the related intellectual property. In accordance with the terms of the Mati Agreement, we received an additional payment of approximately $0.8 million
upon closing (see the Sale of Assets and Discontinued Operations Punctal Plug Delivery Program above for additional information).
25
The sale proceeds discussed above and the results of operations relating to both our PPDS
Technology and Visudyne transactions have been excluded from continuing operations and reported as discontinued operations for all periods presented. See Note 8
Discontinued Operations and Assets Held for Sale
in the Notes to our
Unaudited Condensed Consolidated Financial Statements.
Income Taxes
During the three and nine months ended September 30, 2013, the provision for income taxes was $0.1 million and $0.4 million, respectively.
The provision in each period primarily relates to the current period gain on the fair value change of our Eligard related contingent consideration. In addition, the provisions also reflect that we have insufficient evidence to support current or
future realization of the tax benefits associated with our development expenditures.
During the three and nine months ended
September 30, 2012, we recorded net income tax recoveries of $4.3 million and $3.8 million, respectively. The recovery in each period primarily related to the recognition of the tax benefit of our operating losses from continuing
operations. As a result of the sale of Visudyne to Valeant during the three months ended September 30, 2012, we benefited from a portion of our operating losses from continuing operations.
During the three and nine months ended September 30, 2013, the provision for income taxes related to discontinued operations was nil and
$0.2 million, respectively. The provision during the nine months ended September 30, 2013 primarily relates to the drawdown of a prepaid tax asset that was recorded in a prior year in connection with the intercompany transfer of certain
intellectual property and the subsequent sale of such technology to Mati in April 2013. The provisions for income taxes on discontinued operations also reflects that we have insufficient evidence to support current or future realization of the tax
benefits associated with expenditures related to our discontinued operations.
During the three and nine months ended September 30,
2012, the provision for income taxes related to discontinued operations was $5.3 million and $5.5 million, respectively. The provision in each period primarily related to the recognition of the tax cost of utilizing the tax shield associated with
our operating losses realized from continuing operations. The provision in each period also reflected that substantially all of the remaining balance of the tax impact of the gain on sale from discontinued operations was offset by tax basis and
other tax attributes (e.g. loss carryforwards) which previously had a valuation allowance.
As insufficient evidence exists to support
current or future realization of the tax benefits associated with the vast majority of our current and prior period operating expenditures, the benefit of certain tax assets was not recognized during the three and nine months ended
September 30, 2013 and 2012.
The net deferred tax asset of $0.5 million as of September 30, 2013 was largely the result of
contingent consideration, and other temporary differences against which a valuation allowance was not applied.
As of September 30,
2013, we had a valuation allowance against specifically identified tax assets. The valuation allowance is reviewed periodically and if managements assessment of the more likely than not criterion for accounting purposes changes,
the valuation allowance is adjusted accordingly.
LIQUIDITY AND CAPITAL RESOURCES
General
As at September 30, 2013,
our cash resources, working capital, cash from divestitures, cash collected from contingent consideration, and other available financing resources are sufficient to service current product research and development needs, operating requirements,
liability requirements, milestone payments, and restructuring and change in control obligations.
26
However, factors that may affect our future capital availability or requirements may include:
returns of capital to shareholders, including future share repurchases; the status of competitors and their intellectual property rights; levels of future sales of Eligard and our receipt of contingent consideration under the QLT USA stock purchase
agreement with Tolmar; levels of future sales of Visudyne and receipt of contingent consideration under the Valeant Agreement; the progress of our R&D programs, including preclinical and clinical testing; the timing and cost of obtaining
regulatory approvals; the levels of resources that we devote to the development of manufacturing and other support capabilities; technological advances; the cost of filing, prosecuting and enforcing our patent claims and other intellectual property
rights; pre-launch costs related to commercializing our products in development; acquisition and licensing activities; milestone payments and receipts; our ability to establish collaborative arrangements with other organizations; and the pursuit of
future financial and/or strategic alternatives.
There is no guarantee that our future liquidity and capital resources will be sufficient
to service our operating needs and financial obligations. In this event, our business could be materially and adversely affected and the Company would be required to seek other financing alternatives.
Sources and Uses of Cash
We finance
operations, product development and capital expenditures primarily through existing cash and contingent consideration received from previous asset sales and interest income.
During the three months ended September 30, 2013, we used $5.0 million of cash in operations compared to $10.5 million for the same
period in 2012. The $5.5 million positive cash flow variance was primarily attributable to the following:
|
|
|
A positive operating cash flow variance from lower operational spending of $5.4 million resulting from our 2012 restructuring initiatives;
|
|
|
|
A positive operating cash flow variance from lower spending on restructuring costs of $9.5 million;
|
|
|
|
A negative operating cash flow variance from lower cash receipts from product sales and royalties of $7.8 million, resulting from our 2012
divestiture of our Visudyne business to Valeant; and
|
|
|
|
A negative operating cash flow variance from a decrease of $1.6 million in other income.
|
During the three months ended September 30, 2013, cash flows provided by investing activities primarily consisted of $8.5 million of
contingent consideration received in connection with our previous sale QLT USA (see
Sale of Assets and Discontinued OperationsEligard
above for additional information); $7.5 million of proceeds, related to our 2012 sale of Visudyne,
which was released to us on September 26, 2013 from an escrow account; and $0.1 million spent on capital expenditures.
During the three months ended
September 30, 2013, there were no cash flows related to financing activities.
For the nine months ended September 30, 2013, we
used $20.7 million of cash in operations compared to $33.4 million for the same period in 2012. The $12.7 million positive cash inflow variance was primarily attributable to the following:
|
|
|
A positive operating cash flow variance from lower operational spending of $32.7 million;
|
|
|
|
A positive operating cash flow variance from lower spending on restructuring costs of $6.8 million;
|
|
|
|
A negative operating cash flow variance from lower cash receipts from product sales and royalties of $23.9 million, resulting from our 2012
divestiture of our Visudyne business to Valeant; and
|
|
|
|
A negative operating cash flow variance from a decrease of $2.9 million in other income.
|
27
During the nine months ended September 30, 2013, cash flows provided by investing activities
consisted of $25.0 million of contingent consideration received in connection with our previous sale of QLT USA; $7.5 million of proceeds released from escrow as described above; $0.7 million of proceeds related to our sale of our PPDS Technology;
and $0.2 million of proceeds from the sale of certain assets and property, plant and equipment, that was previously designated as held-for-sale.
During the nine months ended September 30, 2013, cash flows used in financing activities included the $200.0 million Cash
Distribution to shareholders and $14.1 million of cash used to repurchase common shares, including share repurchase costs. These cash outflows were partially offset by $8.3 million of cash received for the issuance of common shares related to the
exercise of stock options.
Interest and Foreign Exchange Rates
We are exposed to market risk related to changes in interest and foreign currency exchange rates, each of which could adversely affect the
value of our current assets and liabilities. At September 30, 2013, we had $114.1 million in cash and cash equivalents and our cash equivalents had an average remaining maturity of approximately 17 days. If market interest rates were to
increase immediately and uniformly by one hundred basis points from levels at September 30, 2013, the fair value of the cash equivalents would decline by an immaterial amount due to the short remaining maturity period.
The functional currency of QLT Inc. and its U.S. subsidiaries is the U.S. dollar and, therefore, our U.S. dollar-denominated cash and cash
equivalents holdings do not result in foreign currency gains or losses in operations. To the extent that QLT Inc. holds a portion of its monetary assets and liabilities in Canadian dollars, we are subject to translation gains and losses. These
translation gains and losses are included in operations for the period.
At September 30, 2013, we had no outstanding forward foreign
currency contracts and no collateral was pledged for security.
Contractual Obligations
Our material contractual obligations as of September 30, 2013 consist of our clinical and development agreements. We currently have a two
year operating lease commitment, which commenced on September 1, 2013, for approximately 20,000 square feet of office and laboratory space. As at September 30, 2013, we no longer have any operating lease commitments in the U.S. for office
space, office equipment, or vehicles.
Off-Balance Sheet Arrangements
In connection with the sale of assets and businesses, we provide indemnities related to certain matters; including product liability, patent
infringement, and contract breach and misrepresentation. We also provide other indemnities to parties under the clinical trial, license, service, manufacturing, supply and other agreements that we enter into in the normal course of our business. If
the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnities are generally subject to certain threshold amounts, specified claims periods and other
restrictions and limitations.
Except as described above and the contractual arrangements described in the
Contractual Obligations
section above, we do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future impact on our financial condition, changes in financial condition, revenues or expenses, results of
operations, liquidity, capital expenditures or capital resources.
Outstanding Share Data
On April 25, 2013, the Companys board of directors amended and restated the QLT 2000 Incentive Stock Plan (the Plan) to
increase the number of shares of the Companys common stock, without par value, available for grant under the Plan from 7,800,000 to 11,800,000 and to make certain other amendments to the Plan, including
28
to permit the granting of restricted stock units (RSUs) under the Plan. The amendment and restatement of the Plan was subject to shareholder approval, which was obtained on
June 14, 2013. On July 29, 2013, the Company filed a registration statement to register the issuance of up to an additional 4,000,000 common shares that may be issued under the Plan as a result of the amendment to the Plan.
On July 15, 2013, the Board of Directors granted an aggregate of 862,000 stock options to employees and 100,000 stock options to
directors. The stock options vest and become exercisable in thirty-six (36) successive and equal monthly installments beginning on the one-month anniversary of the date of grant and have an exercise price of CAD $4.54 per share, which is equal
to the closing price of the Companys common shares on the Toronto Stock Exchange on the date of grant.
On July 15, 2013,
48,000 RSUs were issued to directors under the Plan in consideration of their provision of future services as directors. The RSUs vest in three (3) successive and equal yearly installments on the date of each of the first three
annual general meetings of the Company held after the date of grant. Upon vesting, each RSU represents the right to receive one common share of the Company.
On July 15, 2013, the Board of Directors granted 88,000 deferred share units (DSUs) to directors under the
Directors Deferred Share Unit Plan (the DDSU Plan). The DSUs vest in thirty-six (36) successive and equal monthly installments beginning on the first day of the first month after the date of grant. A vested DSU can only be
settled by conversion to cash (i.e. no shares are issued), and is automatically converted after the director ceases to be a member of the Board unless the director is removed from the Board for just cause.
As of November 5, 2013, there were 51,081,878 common shares issued and outstanding, which totaled $466.2 million in share capital. As of
November 5, 2013, we had 1,074,348 stock options outstanding (of which 147,406 were exercisable) at a weighted average exercise price of CAD $5.64 per share. Each stock option is exercisable for one common share. As of November 5, 2013, we had
48,000 RSUs outstanding (none of which are vested). Upon vesting, each RSU represents the right to receive one common share of the Company.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the periods presented.
Significant estimates include; but are not limited to; the measurement of contingent consideration at fair value, allocation of overhead expenses to research and development, stock-based compensation, and provisions for taxes, tax assets and
liabilities. Actual results may differ from estimates made by management. Please refer to our Critical Accounting Policies and Estimates included as part of our 2012 Annual Report.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and
forward looking information within the meaning of the Canadian securities legislation which are based on our current expectations and projections. Words such as anticipate, project, potential,
goal, believe, expect, forecast, outlook, plan, intend, estimate, should, may, assume, continue and
variations of such words or similar expressions are intended to identify our forward-looking statements and forward-looking information. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of QLT to be materially different from the results of operations or plans expressed or implied by such forward-looking statements and forward-looking information. Many such risks, uncertainties and other factors
are taken into account as part of our assumptions underlying the forward-looking statements and forward-looking information.
29
The following factors, among others, including those described in Item 1A. of our Annual
Report on Form 10-K for the year ended December 31, 2012 (the 2012 Annual Report), as amended in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 (the Q1 2013 Quarterly Report) and our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 (the Q2 2013 Quarterly Report), could cause our future results to differ materially from those expressed in the forward-looking statements and forward-looking
information:
|
|
|
our expectations regarding the results of our strategic restructuring;
|
|
|
|
unanticipated negative effects of our strategic restructuring;
|
|
|
|
our ability to maintain adequate internal controls over financial reporting;
|
|
|
|
our ability to retain or attract key employees, including a new Chief Executive Officer;
|
|
|
|
the anticipated timing, cost and progress of the development of our technology and clinical trials;
|
|
|
|
the anticipated timing of regulatory submissions for product candidates;
|
|
|
|
the anticipated timing for receipt of, and our ability to maintain, regulatory approvals for product candidates;
|
|
|
|
our ability to successfully develop and commercialize our synthetic retinoid program;
|
|
|
|
existing governmental laws and regulations and changes in, or the failure to comply with, governmental laws and regulations;
|
|
|
|
the scope, validity and enforceability of our and third party intellectual property rights;
|
|
|
|
the anticipated timing for receipt of, and our ability to obtain and maintain, orphan drug designations for our synthetic retinoid;
|
|
|
|
receipt of all or part of the contingent consideration pursuant to the stock purchase agreement entered into with Tolmar, which is based on
anticipated levels of future sales of Eligard;
|
|
|
|
receipt of the full Laser Earn-Out Payment, which is currently subject to the dispute with Valeant, and receipt of all or part of the other
contingent consideration pursuant to the Valeant Agreement, which is based on future sales of Visudyne outside of the United States and sales attributable to any new indications for Visudyne;
|
|
|
|
receipt of all or part of the contingent consideration pursuant to the asset purchase agreement with Mati based on Matis successful
development and sales of products based on our PPDS Technology;
|
|
|
|
our ability to effectively market and sell any future products;
|
|
|
|
changes in estimates of prior years tax items and results of tax audits by tax authorities; and
|
|
|
|
unanticipated future operating results.
|
Although we believe that the assumptions underlying the forward-looking statements and forward-looking information contained herein are
reasonable, any of the assumptions could be inaccurate, and therefore such statements and information included in this Quarterly Report may not prove to be accurate. In light of the significant uncertainties inherent in the forward-looking
statements and forward-looking information included herein, the inclusion of such statements and information should not be regarded as a representation by us or any other person that the results or conditions described in such statements and
information or our objectives and plans will be achieved. Any forward-looking statement and forward-looking information speaks only as of the date on which it is made. Except to fulfill our obligations under the applicable securities laws, we
undertake no obligation to update any such statement or information to reflect events or circumstances occurring after the date on which it is made.
30